Global RNAi for Therapeutic Market by Manufacturers, Regions, Type and Application, Forecast to 2021
RNA interference (RNAi) is a biological process in which RNA molecules inhibit gene expression, typically by causing the destruction of specific mRNA molecules. Historically, it was known by other names, including co-suppression, post-transcriptional gene silencing (PTGS), and quelling. Only after these apparently unrelated processes were fully understood did it become clear that they all described the RNAi phenomenon. RNAi is now known as precise, efficient, stable and better than antisense technology for gene suppression.
Scope of the Report:
This report focuses on the RNAi for Therapeutic in Global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
Market Segment by Manufacturers, this report covers
Alnylam Pharmaceuticals
Arbutus Biopharma (Tekmira)
Arrowhead
Dicerna Pharmaceuticals
Mirna Therapeutics
Quark Pharmaceuticals
RXi Pharmaceuticals
Silence Therapeutics
Benitec Biopharma
miRagen Therapeutics
Sylentis
Gradalis
Sirnaomics
Silenseed
Market Segment by Regions, regional analysis covers
North America (USA, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America, Middle East and Africa
Market Segment by Type, covers
siRNA
miRNA
shRNA
Market Segment by Applications, can be divided into
Cancer
Cardiovascular
HBV
Other
There are 13 Chapters to deeply display the global RNAi for Therapeutic market.
Chapter 1, to describe RNAi for Therapeutic Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of RNAi for Therapeutic, with sales, revenue, and price of RNAi for Therapeutic, in 2015 and 2016;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2015 and 2016;
Chapter 4, to show the global market by regions, with sales, revenue and market share of RNAi for Therapeutic, for each region, from 2011 to 2016;
Chapter 5, 6, 7 and 8, to analyze the key regions, with sales, revenue and market share by key countries in these regions;
Chapter 9 and 10, to show the market by type and application, with sales market share and growth rate by type, application, from 2011 to 2016;
Chapter 11, RNAi for Therapeutic market forecast, by regions, type and application, with sales and revenue, from 2016 to 2021;
Chapter 12 and 13, to describe RNAi for Therapeutic sales channel, distributors, traders, dealers, appendix and data source.
Scope of the Report:
This report focuses on the RNAi for Therapeutic in Global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
Market Segment by Manufacturers, this report covers
Alnylam Pharmaceuticals
Arbutus Biopharma (Tekmira)
Arrowhead
Dicerna Pharmaceuticals
Mirna Therapeutics
Quark Pharmaceuticals
RXi Pharmaceuticals
Silence Therapeutics
Benitec Biopharma
miRagen Therapeutics
Sylentis
Gradalis
Sirnaomics
Silenseed
Market Segment by Regions, regional analysis covers
North America (USA, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America, Middle East and Africa
Market Segment by Type, covers
siRNA
miRNA
shRNA
Market Segment by Applications, can be divided into
Cancer
Cardiovascular
HBV
Other
There are 13 Chapters to deeply display the global RNAi for Therapeutic market.
Chapter 1, to describe RNAi for Therapeutic Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of RNAi for Therapeutic, with sales, revenue, and price of RNAi for Therapeutic, in 2015 and 2016;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2015 and 2016;
Chapter 4, to show the global market by regions, with sales, revenue and market share of RNAi for Therapeutic, for each region, from 2011 to 2016;
Chapter 5, 6, 7 and 8, to analyze the key regions, with sales, revenue and market share by key countries in these regions;
Chapter 9 and 10, to show the market by type and application, with sales market share and growth rate by type, application, from 2011 to 2016;
Chapter 11, RNAi for Therapeutic market forecast, by regions, type and application, with sales and revenue, from 2016 to 2021;
Chapter 12 and 13, to describe RNAi for Therapeutic sales channel, distributors, traders, dealers, appendix and data source.
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
Please Select a Format
